For People Losing Weight with GLP-1, How Much Cardiovascular Benefit Is There Really?
After a shot of a GLP-1 weight-loss drug, the number on the scale goes down—but does your heart truly benefit as well? The SELECT trial, published in the New England Journal of Medicine (NEJM) in 2023, delivered an answer that shook the entire cardiovascular field: in people with established cardiovascular disease who were overweight or obese but did not have diabetes, semaglutide reduced the risk of major adverse cardiovascular events (MACE) by 20%. This is not mouse data from a laboratory, but hard-endpoint evidence covering nearly 20,000 patients with follow-up of up to 5 years. Since then, GLP-1 has no longer been just a "weight-loss shot"—it is reshaping the treatment landscape for cardiometabolic disease.This article is for health education and informational reference only and does not constitute medical advice; if you have health concerns, please consult a professional physician.
I. Data Impact: How Strong Is the Cardiovascular Evidence for GLP-1?
More than 1 billion people worldwide are affected by obesity (World Obesity Federation, 2025), and cardiovascular disease causes approximately 17.9 million deaths each year (WHO, 2024). The relationship between weight loss and cardiovascular protection has long lacked direct drug-level evidence. The emergence of GLP-1 receptor agonists (GLP-1 RAs) has filled this gap. Below are the core data from several key cardiovascular outcome trials (CVOTs):| Trial Name | Drug | Population | Sample Size | MACE Risk Reduction | Year Published |
|---|---|---|---|---|---|
| SELECT | Semaglutide | Obesity/overweight + established CVD, no diabetes | 17,604 | 20% | 2023 (NEJM) |
| SURPASS-CVOT | Tirzepatide vs semaglutide | Type 2 diabetes + ASCVD | 13,534 | Tirzepatide noninferior, MACE hazard ratio 0.87 | 2025 (NEJM) |
| STEP-HFpEF | Semaglutide | Obesity + HFpEF, no diabetes | 529 | Significant improvement in heart failure symptoms, increased 6-minute walk distance | 2023 (NEJM) |
| Harmony Outcomes | Albiglutide | Type 2 diabetes + CVD | 9,463 | 22% | 2018 (Lancet) |
| REWIND | Dulaglutide | Type 2 diabetes (including high CV risk) | 9,901 | 12% | 2019 (Lancet) |
MACE = composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Risk reductions are all compared with placebo or comparator drug.
II. 5 Key Points You Need to Know
1. Cardioprotection Is More Than a "Byproduct of Weight Loss"
In the SELECT trial, the semaglutide group lost an average of about 9.4% of body weight, but statistical analysis showed that a trend toward cardiovascular benefit emerged before significant weight loss occurred. The researchers believe that GLP-1 RAs may directly protect the cardiovascular system through multiple pathways—including anti-inflammatory effects, improved endothelial function, and regulation of blood pressure and lipids—rather than relying solely on the single pathway of "getting thinner."2. Who May Benefit More?
Based on the available evidence, the following groups have the strongest evidence of benefiting from the cardiovascular protection of GLP-1 RAs: patients with established atherosclerotic cardiovascular disease (ASCVD) (history of myocardial infarction, stroke, or peripheral artery disease); patients with cardiovascular disease combined with overweight/obesity; patients with type 2 diabetes combined with at least one cardiovascular risk factor; and patients with obesity combined with heart failure with preserved ejection fraction (HFpEF)—the STEP-HFpEF trial showed significant improvements in symptoms and exercise capacity. Notably, the 2025 SURPASS-CVOT results indicate that tirzepatide (a GIP/GLP-1 dual receptor agonist) is non-inferior to semaglutide in terms of cardiovascular benefit in people with type 2 diabetes and ASCVD, providing clinicians with more options.3. Blood Pressure, Lipids, and Waist Circumference Are All Improving
Beyond hard endpoints, GLP-1 RAs also bring improvements in multiple metabolic indicators: systolic blood pressure decreases by an average of about 2–5 mmHg; triglycerides decrease and high-density lipoprotein cholesterol (HDL-C) increases slightly; inflammatory markers such as C-reactive protein (CRP) decrease; and waist circumference shrinks significantly—central obesity is an important driver of cardiovascular risk. Together, these changes form the metabolic basis of the cardiovascular benefits.4. Not Suitable for Everyone—Exercise Caution in These Situations
GLP-1 RAs are not a "universal heart drug," and extra caution is needed in the following situations: personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2): contraindicated; severe gastrointestinal disease (such as inflammatory bowel disease or delayed gastric emptying): may worsen symptoms; history of pancreatitis: risk must be fully assessed; severe renal impairment: dose adjustment or avoidance is needed; pregnancy/lactation: not recommended. Common adverse reactions include gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation, most of which appear early in treatment and lessen over time. Whether GLP-1 RAs are suitable, which one to use, and for how long must be determined by a doctor based on individual circumstances.5. Lifestyle Intervention Remains the Cornerstone
This cannot be emphasized enough: medication is a tool, not a substitute. Clinical trials of GLP-1 RAs were conducted on top of background therapy (including lifestyle intervention and standard cardiovascular drug treatment). A reasonable diet, regular exercise, smoking cessation and limited alcohol intake, and sleep management—these measures that require no prescription—must work in concert with medication to achieve the greatest benefit. The issue of weight rebound after stopping the drug has also been confirmed by multiple studies. If sustainable lifestyle habits are not established during treatment, weight and metabolic indicators may rise again after discontinuation, and the cardiovascular benefits may weaken accordingly.III. Action Recommendations: What Should You Do?
If you are a member of the general public:- Pay attention to waist circumference (ideally <90 cm for men and <85 cm for women); it reflects central obesity and cardiovascular risk better than BMI
- Regularly monitor blood pressure, fasting blood glucose, and blood lipids (especially triglycerides and HDL-C)
- If you already have cardiovascular disease and are overweight/obese, you can discuss with your doctor at your next visit whether GLP-1 RA is suitable for you—but please do not purchase and use the medication on your own
- For patients with ASCVD and overweight/obesity, the SELECT evidence may be referenced to assess the cardiovascular benefits of GLP-1 RA therapy
- Before prescribing, screen for contraindications related to the thyroid, pancreas, gastrointestinal tract, and renal function
- After prescribing, monitor changes in heart rate, gastrointestinal tolerance, and weight changes, and conduct regular follow-up